September 18, 2025- McKesson Company introduced adjustments in its reportable segments and organizational construction, successfully within the second quarter of the tax 12 months 2026. The brand new reporting construction improves strategic coordination and transparency, in assist of optimizing portfolio cage for shareholders' lane worth creation.

“McKesson has an extended historical past of well being care management, which is consistently evolving to satisfy the wants of our clients, suppliers and the sufferers we serve collectively,” stated Britt Vitalone, Chief Monetary Officer. “This up to date reporting construction displays a strategic evolution of our company-de progress in areas with excessive margins of oncology, multisecialty and biopharma providers. It improves transparency and strengthens our disciplined method to capital allocation and shareholder worth.”

Extra particulars are shared through the upcoming Investor Day of the corporate on Tuesday 23 September 2025.

The brand new reportable segments are:

• North American pharmaceutical: A Newly outlined reportable phase that mixes McKesson's scaled wholesale distribution corporations in the US and Canada. It gives best-in-class distribution providers to a large buyer base, together with retail and group pharmacies and institutional care suppliers.
• Oncology and Multispecialty: A newly outlined reportable phase with a portfolio of built-in options in oncology and multisecialty suppliers and options. The phase consists of options for particular supplier, together with distribution -related choices, comparable to specialist drug distribution and group gross sales organizations; And sensible administration providers that assist the most important oncological networks based mostly on the group by medical doctors. The phase additionally consists of different multisecialty suppliers, together with retina and ophthalmology, and presents scientific trial providers, options for specialties and entry to superior analysis, along with innovation via technology-driven insights.
• Options for prescription know-how: Connects sufferers, pharmacies, suppliers, pharmacy profit managers, well being plans and biopharma via scaled, differentiated networks, enhancing the entry and affordability of medicines, whereas offering measurable worth to Biopharma.
• Surgical Options: Supplies medical-surgical supply distribution, logistics and different associated providers to healthcare suppliers at different care areas. In Might 2025, McKesson introduced his intention to separate this phase into an unbiased firm.
• Different: Distribution and retail actions in Norway. On August 4, 2025, McKesson concluded a ultimate settlement to promote our corporations in Norway. The transaction is topic to typical closing situations, together with receipt of the required approvals of the laws.

Seek the advice of right this moment a separate 8-Ok submitted to the Securities and Change Fee for extra historic info by new reportable segments for the tax quarters ending on 30 June 2024, 30 September 2024, 31 December 2024, 31 March 2025 and 30 June 2025, for the tax years ending on March 31, 2024 and 2025.

Upcoming investor day

McKesson is organizing his investor day on Tuesday 23 September 2025 at 9:30 am et. The occasion will current displays of the McKesson management workforce and a stay Q&A session with Chief Government Officer Brian Tyler and Chief Monetary Officer Britt Vitalone. The video -webcast and extra particulars can be found on the McKesson's Investor Relations web site.

Learn the press launch right here.